Barinthus Biotherapeutics (BRNS) announced the promotion of Geoffrey Lynn to chief scientific officer, or CSO, effective as of December 1. Lynn succeeds Nadege Pelletier, who decided to pursue alternative opportunities closer to home after having served as Barinthus Bio’s CSO since early 2023.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRNS:
- Barinthus Biotherapeutics Reports Promising IM-PROVE II Trial Results
- Barinthus announces results from ongoing Phase 2b HBV003 trial
- Arbutus and Barinthus announce new data from IM-PROVE II trial
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Barinthus Biotherapeutics reports Q3 EPS (21c), consensus (44c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue